샘플 요청 목록

 카트 문의
시장보고서
상품코드
1663312

신경혈관 색전 디바이스 : 시장 인사이트, 경쟁 구도, 시장 예측(2032년)

Neurovascular Embolization Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032
발행일: | 리서치사: DelveInsight | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

세계의 신경혈관 색전 디바이스 시장 규모는 2024년에 13억 4,766만 달러로, 2032년까지 18억 9,084만 달러에 달할 것으로 예측되며, 2025-2032년의 예측 기간에 CAGR로 4.40%의 성장이 전망됩니다. 동맥류, 심한 두부 외상, 좌식 생활 습관, 허혈성 뇌졸중과 같은 신경혈관 질환의 유병률 증가가 세계 신경혈관 색전 장비 시장을 크게 견인하고 있습니다. 이러한 질환은 정확하고 최소 침습적인 치료가 필요한 경우가 많으며, 이를 위해서는 색전술이 필수적입니다. 또한 신경혈관 질환의 주요 위험요인인 고혈압의 전 세계적인 증가로 인해 뇌출혈과 동맥류 발병률이 높아지면서 효과적인 색전 솔루션에 대한 수요가 더욱 증가하고 있습니다.

주요 시장 기업의 지속적인 제품 개발 활동은 환자 치료 결과와 시술 성공률을 향상시키는 첨단이고 효율적인 색전술 장비를 도입하고 있습니다. 장비 설계, 생체 적합성 및 전달 메커니즘의 혁신은 치료의 정확성과 안전성을 향상시켜 의료진들 사이에서 채택이 확대되고 있습니다.

이러한 요인들을 종합하면 2025-2032년의 예측 기간 중 세계 신경혈관색전술 장비 시장은 상당한 성장을 보일 것으로 예상됩니다.

신경혈관 색전 장비 시장 역학:

Global Burden of Disease(2024)에 따르면 신경질환은 2021년 전 세계 인구의 약 43%, 약 34억 명에게 영향을 미쳤습니다. 그 중 긴장성 두통이 가장 많은 20억 명, 편두통이 약 11억 명으로 추정되며, 그 다음으로 편두통이 약 11억 명에게 영향을 미칩니다. 또한 전 세계 당뇨병성 신경병증의 유병률은 1990년 이후 3배 이상 증가하여 2021년에는 2억 6천만 명에 달할 것으로 예상됩니다. 만성 긴장성 두통은 혈관에 영향을 미치는 경우가 많으며, 당뇨병성 신경병증은 혈관 손상을 일으켜 동맥류 및 동정맥 기형(AVM)과 같은 신경혈관 질환의 위험을 증가시킵니다. 이러한 신경장애의 유병률이 증가함에 따라 뇌졸중 및 기타 혈관 합병증의 위험을 감소시키는 최소침습적 치료법에 대한 수요가 증가하고 있습니다. 비정상적인 혈류를 차단하거나 동맥류를 막는 데 사용되는 신경혈관색전술은 이러한 질환에 대응하는 데 있으며, 점점 더 중요한 역할을 하고 있으며, 이는 세계 시장 성장을 가속하고 있습니다.

이러한 추세를 보완하듯, British Heart Foundation(2024)은 전 세계에서 약 5,600만 명의 여성과 4,500만 명의 남성이 뇌졸중 생존자라고 보고하고 있습니다. 뇌졸중은 혈전이나 동맥류, 뇌내 비정상적인 혈관 형성에 의해 발생하는 경우가 많으며, 혈류를 회복하고 출혈을 예방하기 위해서는 신속한 개입이 필요합니다. 코일, 스텐트, 액체색전제를 포함한 신경혈관색전술 장비는 동맥류를 막고, 혈관의 파열을 막고, 손상된 뇌조직으로의 비정상적인 혈류를 차단하여 이러한 질환을 치료하는 데 필수적이며, 시장 확대를 더욱 촉진하고 있습니다.

질병 유병률 증가와 더불어 제품 개발 활동의 활성화가 시장 성장을 가속할 것으로 예상됩니다. 예를 들어 2021년 4월 Medtronic plc는 혈전 형성을 줄이고 혈류 전환 치료 중 혈전 형성 위험을 낮추도록 설계된 Shield Technology(TM)를 이용한 Pipeline(TM) Flex Neurovascular Embolization(TM)의 FDA 승인을 받았습니다. Device의 FDA 승인을 획득하였습니다.

이러한 성장 촉진요인이 있는 반면, 몇 가지 과제가 시장 발전을 저해할 가능성도 있습니다. 마이크로카테터, 마이크로 가이드와이어, 코일로 인한 동맥류 천공과 같은 색전술과 관련된 합병증은 시술상의 위험을 초래할 수 있습니다. 또한 까다로운 규제 당국의 승인 절차로 인해 제품 출시가 지연되어 시장 성장을 저해할 수 있습니다.

북미가 전체 신경혈관색전술 기기 시장을 독점할 것으로 예상됩니다.

북미는 2024년 세계 신경혈관색전술 장비 시장에서 가장 큰 점유율을 차지합니다. 이 지역 시장 성장은 주로 동맥류, 고혈압, 출혈과 같은 신경혈관 질환의 높은 유병률, 활발한 제품 개발 활동, 정부 지원책에 의해 촉진될 것으로 예상됩니다. 이러한 요인들은 예측 기간(2025-2032년) 동안 시장 확대에 크게 기여할 것으로 예상됩니다.

세계의 신경혈관 색전 디바이스 시장에 대해 조사분석했으며, 시장 규모와 예측, 과거 3년의 제품/기술개발, 시장의 주요 기업, 이용 가능한 기회 등의 정보를 제공하고 있습니다.

목차

제1장 신경혈관 색전 디바이스 시장 보고서 서론

제2장 신경혈관 색전 디바이스 시장 개요

  • 시장의 개요

제3장 경쟁 구도

제4장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제5장 신경혈관 색전 디바이스 시장의 주요 요인 분석

  • 신경혈관 색전 디바이스 시장 촉진요인
  • 신경혈관 색전 디바이스 시장 억제요인과 과제
  • 신경혈관 색전 디바이스 시장의 기회

제6장 신경혈관 색전 디바이스 시장의 Porter's Five Forces 분석

제7장 신경혈관 색전 디바이스 시장 평가

  • 제품 유형별
    • 색전코일
    • 신경혈관 코일 보조 디바이스
    • 액체 색전 시스템
    • Flow Diversion Stents
    • Intrasaccular Flow Disruptor
    • 기타
  • 최종사용자별
    • 병원
    • 외래 수술 센터
  • 지역
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제8장 신경혈관 색전 디바이스 시장의 기업과 제품 개요

  • Medtronic PLC
  • Stryker
  • MicroVention, Inc.(Terumo Corporation)
  • Johnson & Johnson Services, Inc.
  • Penumbra, Inc.
  • B. Braun Melsungen AG
  • Acandis GmbH
  • Wallaby Medical.
  • Shape Memory Medical Inc.
  • Zylox-Tonbridge Medical Technology Co., Ltd.
  • Spartan Micro, Inc.
  • KANEKA CORPORATION
  • Lepu Medical Technology(Beijing) Co., Ltd.
  • Meril Life Sciences Pvt. Ltd.
  • Boston Scientific Corporation
  • phenox GmbH
  • Merit Medical Systems.
  • Perflow Medical Ltd.
  • MicroPort Scientific Corporation.
  • Cerus Endovascular

제9장 KOL의 견해

제10장 프로젝트 어프로치

제11장 DelveInsight 소개

제12장 면책사항, 문의

KSA 25.03.11

Neurovascular Embolization Device Market by Product Type (Embolization Coils, Neurovascular Coil Assist Devices [Coil Assist Stents and Coil Assist Balloons], Liquid Embolization Systems, Flow Diversion Stents, Intrasaccular Flow Disruptor, and Others), By End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of neurovascular disorders, increase in prevalence of hypertension across the globe, and increase in product development activities by the key market players across the globe.

The neurovascular embolization devices market was valued at USD 1,347.66 million in 2024, growing at a CAGR of 4.40% during the forecast period from 2025 to 2032, to reach USD 1,890.84 million by 2032. The rising prevalence of neurovascular disorders such as aneurysms, severe head injuries, sedentary lifestyles, and ischemic strokes is significantly driving the global market for neurovascular embolization devices. These conditions often require precise, minimally invasive treatments, for which embolization devices are critical. Additionally, the global increase in hypertension a major risk factor for neurovascular diseases has led to a higher incidence of brain hemorrhages and aneurysms, further fueling demand for effective embolization solutions.

Ongoing product development efforts by key market players are introducing advanced and efficient embolization devices, improving patient outcomes and procedural success rates. Innovations in device design, biocompatibility, and delivery mechanisms are enhancing treatment precision and safety, thereby expanding adoption among healthcare providers.

Collectively, these factors are expected to drive substantial growth in the global neurovascular embolization devices market during the forecast period from 2025 to 2032.

Neurovascular Embolization Devices Market Dynamics:

According to the Global Burden of Disease (2024), neurological conditions affected approximately 43% of the global population in 2021, impacting around 3.4 billion individuals. Among these, tension-type headaches were the most prevalent, with an estimated 2 billion cases, followed by migraines affecting approximately 1.1 billion people. Additionally, the global prevalence of diabetic neuropathy has more than tripled since 1990, reaching 206 million cases in 2021. Chronic tension headaches often have vascular implications, while diabetic neuropathy can lead to vascular damage, increasing the risk of neurovascular conditions such as aneurysms and arteriovenous malformations (AVMs). As the incidence of these neurological disorders rises, the demand for minimally invasive treatments to mitigate the risks of stroke and other vascular complications is growing. Neurovascular embolization devices used to block abnormal blood flow or seal aneurysms play an increasingly vital role in addressing these conditions, thereby driving global market growth.

Complementing these trends, the British Heart Foundation (2024) reported that approximately 56 million women and 45 million men worldwide were stroke survivors. Strokes, often caused by blood clots, aneurysms, or abnormal blood vessel formations in the brain, require prompt intervention to restore blood flow and prevent hemorrhagic events. Neurovascular embolization devices including coils, stents, and liquid embolic agents are essential in treating these conditions by sealing aneurysms, preventing vessel ruptures, and blocking abnormal blood flow to damaged brain tissue, further propelling market expansion.

In addition to rising disease prevalence, increasing product development activities are expected to bolster market growth. For instance, in April 2021, Medtronic plc received FDA approval for its Pipeline(TM) Flex Neurovascular Embolization Device with Shield Technology(TM), designed to reduce thrombogenicity and lower the risk of clot formation during flow diversion therapy.

Despite these growth drivers, certain challenges may impede market progress. Complications associated with embolization procedures such as aneurysmal perforations caused by micro catheters, micro-guidewires, or coils pose procedural risks. Moreover, stringent regulatory approval processes can delay product launches, potentially restraining market growth.

Neurovascular Embolization Devices Market Segment Analysis:

Neurovascular Embolization Device Market by Product Type (Embolization Coils, Neurovascular Coil Assist Devices [Coil Assist Stents and Coil Assist Balloons], Liquid Embolization Systems, Flow Diversion Stents, Intrasaccular Flow Disruptor, and Others), By End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the global neurovascular embolization devices market, embolization coils are projected to hold the largest share in 2024. These coils, typically made from platinum or other biocompatible materials, are inserted into aneurysms to promote clot formation, effectively sealing the aneurysm and preventing rupture. As a minimally invasive alternative to open surgery, embolization coils offer patients faster recovery times and lower complication risks, making them a preferred choice in neurovascular procedures.

Technological advancements such as improved coil flexibility, enhanced precision, and better radiopacity have further driven their adoption in both emergency and elective neurovascular treatments. These innovations enable physicians to navigate complex vascular anatomies more efficiently, improving procedural success rates and patient outcomes.

Moreover, increased funding for the development and commercialization of neurovascular embolization coils is contributing to market growth. For example, in July 2021, Zylox-Tonbridge Medical Technology Co., Ltd. raised USD 329 million to support the development of its core neurovascular products, including embolization coils and micro catheters for coiling procedures.

Collectively, these factors are expected to generate significant revenue for the embolization coil segment, driving the overall growth of the global neurovascular embolization devices market during the forecast period.

North America is expected to dominate the overall neurovascular embolization devices market:

North America is projected to hold the largest share of the global neurovascular embolization devices market in 2024. The region's market growth is primarily driven by the high prevalence of neurovascular disorders such as aneurysms, hypertension, and hemorrhages coupled with increasing product development activities and supportive government initiatives. These factors are expected to significantly contribute to market expansion during the forecast period (2025 to 2032).

According to the Brain Aneurysm Foundation (2024), an estimated 6.8 million people in the United States approximately 1 in 50 individuals were living with an unruptured brain aneurysm in 2021. The annual rupture rate ranged from 8 to 10 per 100,000 people, with approximately 30,000 aneurysm ruptures occurring each year, translating to one rupture every 18 minutes. This growing diagnosis rate of both ruptured and unruptured aneurysms underscores the need for advanced, minimally invasive treatment solutions. Neurovascular embolization devices including coils, flow diverters, and stents are pivotal in preventing aneurysm ruptures and managing bleeding, offering safer alternatives to traditional open surgeries.

Similarly, the prevalence of strokes further escalates market demand. As per the Centers for Disease Control and Prevention (CDC, 2024), a stroke occurs every 40 seconds in the United States, affecting over 795,000 individuals annually. Of these, approximately 610,000 are first-time strokes, while around 185,000 occur in individuals with a prior stroke. Ischemic strokes caused by blocked blood flow to the brain account for about 87% of these cases. With hypertension being a leading risk factor for both ischemic and hemorrhagic strokes, the growing hypertensive population elevates the incidence of aneurysms, arteriovenous malformations (AVMs), and other neurovascular conditions. Consequently, this drives the need for neurovascular embolization devices to effectively manage and treat these conditions.

Government initiatives aimed at improving brain aneurysm research are further propelling market growth. For example, in March 2021, during the 117th Congressional Session, the U.S. government allocated USD 10 million annually from 2022 to 2030 to support comprehensive research on unruptured intracranial aneurysms, with funds available through September 30, 2029. Such funding is instrumental in fostering technological advancements and improving patient care.

In conclusion, the combination of a high disease burden, technological advancements, supportive policy measures, and increased public awareness is expected to bolster the North American neurovascular embolization devices market during the forecast period.

Neurovascular Embolization Devices Market Key Players:

Some of the key market players operating in the neurovascular embolization devices market include Medtronic PLC, Stryker, MicroVention, Inc. (Terumo Corporation), Johnson & Johnson Services, Inc., Penumbra, Inc., B. Braun Melsungen AG, Acandis GmbH, Wallaby Medical., Shape Memory Medical Inc., Zylox-Tonbridge Medical Technology Co., Ltd., Spartan Micro, Inc., KANEKA CORPORATION, Lepu Medical Technology(Beijing)Co., Ltd., Meril Life Sciences Pvt. Ltd., Boston Scientific Corporation, phenox GmbH, Merit Medical Systems., Perflow Medical Ltd., MicroPort Scientific Corporation., Cerus Endovascular, and others.

Recent Developmental Activities in the Neurovascular Embolization Devices Market:

  • In July 2024, MicroVention, Inc., a neurovascular company and subsidiary of Terumo Corporation, announced the publication of the CLEVER trial results. This multicenter, prospective study involved 163 patients across 17 European centers. Investigators assessed the safety and effectiveness of MicroVention's Woven EndoBridge (WEB) 17 system for treating ruptured and unruptured aneurysms. The WEB 17 is the company's newest and smallest aneurysm embolization system.

Key Takeaways from the Neurovascular Embolization Devices Market Report Study:

  • Market size analysis for current neurovascular embolization devices size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the neurovascular embolization devices market.
  • Various opportunities available for the other competitors in the neurovascular embolization devices market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current neurovascular embolization devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for neurovascular embolization devices market growth in the coming future?

Target Audience Who Can be Benefited from this Neurovascular Embolization Devices Market Report Study:

  • Neurovascular embolization device providers
  • Research organizations and consulting companies
  • Neurovascular embolization devices -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in neurovascular embolization devices
  • Various end-users who want to know more about the neurovascular embolization devices market and the latest technological developments in the neurovascular embolization devices market.

Frequently Asked Questions for the Neurovascular Embolization Devices Market:

1. What are neurovascular embolization devices?

  • A neurovascular embolization device is an intravascular implant intended to permanently occlude blood flow to cerebral aneurysms and cerebral arteriovenous malformations.

2. What is the market for neurovascular embolization devices?

  • The neurovascular embolization devices market was valued at USD 1,3477.66 million in 2024, growing at a CAGR of 4.40% during the forecast period from 2025 to 2032, to reach USD 1,890.84 million by 2032.

3. What are the drivers for the neurovascular embolization devices market?

  • The growing prevalence of neurovascular disorders, such as aneurysms, severe head injuries, sedentary lifestyles, and ischemic strokes, is significantly boosting the market for neurovascular embolization devices. Additionally, the global rise in hypertension, a major risk factor for neurovascular diseases, has increased the number of patients susceptible to conditions like brain hemorrhages and aneurysms, thus driving the demand for effective embolization devices. Furthermore, increased product development activities by key market players across the globe are introducing more advanced and efficient embolization solutions, improving outcomes for patients and enhancing procedural success. Together, these factors are expanding the global market for neurovascular embolization devices.

4. Who are the key players operating in the neurovascular embolization devices market?

  • Some of the key market players operating in the neurovascular embolization devices market include Medtronic PLC, Stryker, MicroVention, Inc. (Terumo Corporation), Johnson & Johnson Services, Inc., Penumbra, Inc., B. Braun Melsungen AG, Acandis GmbH, Wallaby Medical., Shape Memory Medical Inc., Zylox-Tonbridge Medical Technology Co., Ltd., Spartan Micro, Inc., KANEKA CORPORATION, Lepu Medical Technology(Beijing)Co., Ltd., Meril Life Sciences Pvt. Ltd., Boston Scientific Corporation, phenox GmbH, Merit Medical Systems., Perflow Medical Ltd., MicroPort Scientific Corporation., Cerus Endovascular, and others.

5. Which region has the highest share in the neurovascular embolization devices market?

  • Among all the regions, North America is expected to hold the largest share of the global neurovascular embolization devices market in 2024. The growing prevalence of neurovascular disorders, such as aneurysms, hypertension, hemorrhages, and others is expected to boost the market across the region. Additionally, recent product developmental activities and rising government initiatives are expected to aid in the growth of the North American neurovascular embolization devices market during the forecast period from 2025 to 2032.

Table of Contents

1. Neurovascular Embolization Devices Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Neurovascular Embolization Devices Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Neurovascular Embolization Devices Market Key Factors Analysis

  • 5.1. Neurovascular Embolization Devices Market Drivers
    • 5.1.1. Growing prevalence of neurovascular disorders such as brain aneurysm, hemorrhage, and others due to severe head injuries, sedentary lifestyle, others
    • 5.1.2. Increase in prevalence of hypertension across the globe
    • 5.1.3. Increase in product development activities by key market players across the globe
  • 5.2. Neurovascular Embolization Devices Market Restraints and Challenges
    • 5.2.1. Complications associated with embolization coils
    • 5.2.2. Stringent regulatory approvals
  • 5.3. Neurovascular Embolization Devices Market Opportunities
    • 5.3.1. Continuous innovations in embolization technology, including more precise, flexible, and safer devices

6. Neurovascular Embolization Devices Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Neurovascular Embolization Devices Market Assessment

  • 7.1. By Product Type
    • 7.1.1. Embolization Coils
    • 7.1.2. Neurovascular Coil Assist Devices
      • 7.1.2.1. Coil Assist Stents
      • 7.1.2.2. Coil Assist Balloons
    • 7.1.3. Liquid Embolization Systems
    • 7.1.4. Flow Diversion Stents
    • 7.1.5. Intrasaccular Flow Disruptor
    • 7.1.6. Others
  • 7.2. By End-User
    • 7.2.1. Hospitals
    • 7.2.2. Ambulatory Surgical Centers
    • 7.2.3. Others
  • 7.3. By Geography
    • 7.3.1. North America
      • 7.3.1.1. United States Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.1.2. Canada Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.1.3. Mexico Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
    • 7.3.2. Europe
      • 7.3.2.1. France Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.2.2. Germany Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.2.3. United Kingdom Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.2.4. Italy Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.2.5. Spain Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.2.6. Rest of Europe Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
    • 7.3.3. Asia-Pacific
      • 7.3.3.1. China Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.3.2. Japan Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.3.3. India Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.3.4. Australia Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.3.5. South Korea Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.3.6. Rest of Asia-Pacific Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
    • 7.3.4. Rest of the World (RoW)
      • 7.3.4.1. Middle East Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.4.2. Africa Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.4.3. South America Neurovascular Embolization Devices Market Size in USD Million (2022-2032)

8. Neurovascular Embolization Devices Market Company and Product Profiles

  • 8.1. Medtronic PLC
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Stryker
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. MicroVention, Inc. (Terumo Corporation)
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Johnson & Johnson Services, Inc.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Penumbra, Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. B. Braun Melsungen AG
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Acandis GmbH
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Wallaby Medical.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Shape Memory Medical Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Zylox-Tonbridge Medical Technology Co., Ltd.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Spartan Micro, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. KANEKA CORPORATION
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Lepu Medical Technology (Beijing)Co., Ltd.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Meril Life Sciences Pvt. Ltd.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Boston Scientific Corporation
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. phenox GmbH
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Merit Medical Systems.
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Perflow Medical Ltd.
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. MicroPort Scientific Corporation.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Cerus Endovascular
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제